Portfolio Strategy

Program-by-program assessment

Each program evaluated at the study level: scientific rationale, competitive landscape, preclinical feasibility, regulatory path, and commercial potential.

Indication and target evaluation

For platform companies or teams weighing multiple indications: unmet need, competitive dynamics, model availability, regulatory precedent, and time to value inflection.

Head-to-head comparison matrix

Programs scored and ranked across key dimensions so the trade-offs are visible and defensible, not buried in narrative.

Go/no-go decision framework

Clear criteria for each program: what data you need to see, what would trigger a pivot, and what would justify continued investment.

Next-study plan per program

Specific next steps for each program with model, endpoints, timeline, and estimated budget. Not generic recommendations.

Resource allocation and sequencing

Where to concentrate budget and team bandwidth. Which programs to advance, which to deprioritize, and in what order.

Program budget and timeline

Consolidated view across all programs with milestone dependencies, so you can plan capital allocation against real development timelines.

Board-ready narrative

Executive summary with visual program map, prioritization rationale, and recommended next steps. Built for direct use in board meetings and investor conversations.